Understanding how the liver controls apoB-containing lipoproteins that may raise heart disease risk
Official title: Novel regulatory mechanisms controlling hepatic apoB-Lp lipid loading and secretion
Funded at New York University D/b/a NYU Long Island School of Medicine · NIH-11327669 · Data updated 2026-11-12
Researchers are studying how the liver makes apoB-containing lipoproteins like VLDL and how fat and lipolysis signaling influence this process to better prevent atherosclerotic disease.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University D/b/a NYU Long Island School of Medicine NIH-funded |
| Lab location | 1 site (Mineola, United States) |
| Project start | May 1, 2023 |
| Project end | April 30, 2028 |
| Funding year | 2026 |
| Award (this year) | $460,343 |
| NIH project number | 5P01HL160470-04 |
| Project ID | NIH-11327669 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are adults with or at high risk for atherosclerotic cardiovascular disease who are interested in future translational opportunities or biomarker studies linked to lipoprotein biology.
✕Less likely to help
Individuals without ASCVD risk factors or lipoprotein abnormalities may see limited direct benefit from this basic mechanistic research.
What this research studies
This grant explores how crosstalk between fat tissue and the liver affects the production of apoB-containing lipoproteins that contribute to arterial plaque. It focuses on the liver-specific steps that generate apoB/VLDL, including how ER-associated degradation and lipidation determine particle formation. By mapping how lipids and protein pathways interact, the work aims to identify points where future therapies could reduce the number of atherogenic particles in the blood. The project builds on prior findings and uses cellular and molecular approaches to illuminate who and how these lipoproteins are assembled and secreted.
Why it matters
Potential benefit: If successful, the research could reveal new targets to reduce harmful lipoprotein production and lower ASCVD risk.
How similar studies have gone: Previous work from the investigators has yielded multiple publications and foundational insights into apoB/VLDL regulation, supporting potential for meaningful advances.
Where this research is happening
-
New York University D/b/a NYU Long Island School of Medicine
Mineola, United States Active
Researchers
- Principal investigator: Fisher, Edward a — New York University D/b/a NYU Long Island School of Medicine
- Study coordinator: Fisher, Edward a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.